Initiation of Risk Assessments

by | May 2, 2022 | Compliance, Consulting Group, FDA, Quality, Risk Management, Standardization, Standards

Risk Assessments are a powerful tool used to elevate regulatory decisions and product changes. Risk assessments are analyzed iteratively to refine the assessment questions, data, and assumptions. Information is exchanged between the risk assessment team and stakeholders within the industry; communication, participation, and collaboration are encouraged in the risk assessment process. A risk assessment provides information on the characteristics of the risk attributed to a hazard.

Device needs, resources, and public health concerns are major considerations in the determination of a risk assessment. The best method for initiation of a risk analysis process includes:

  • Establishing a procedure
  • Develop criteria to evaluate the quality of data
  • Develop guidelines to evaluate
  • Formalize a review process
  • Increase capacity to conduct risk assessments1

Risk management and risk communications are the other key factors in the risk assessment process. Risk management activities are to control the hazards involved in the process. Risk communication incorporates the exchange of information and opinions about the risks. Most risk assessments are iterative, transparent, team-oriented, and collaborative and should be applied to all risk analysis steps1. During the risk assessment process research is usually conducted to discover missing information on the risk mitigation.

The risk management team assembles the appropriate data to draft the technical and interpretive risk assessment summary documents. Depending on the intensity of the risk assessment, the Food and Drug Administration (FDA) staff or other agencies may review summary documents, as necessary. If your company needs assistance with the initiation of a risk assessment EMMA International can assist. Contact us by phone at 248-987-4497 or by email at info@emmainternational.com.

_______________________

1FDA (March 2018). Initiation and conduct all major risk assessments within risk analysis framework Retrieved on APR 25, 2022 from https://www.fda.gov/food/cfsan-risk-safety-assessments/initiation-and-conduct-all-major-risk-assessments-within-risk-analysis-framework

Sarah Koehler

Sarah Koehler

Sarah is a Quality Engineer at EMMA International. She has experience in quality assurance, change management, laboratory controls, and process/equipment validation within the pharmaceutical and medical device industry. Sarah has earned a Bachelor of Science in Chemical Engineering from Western Michigan University.

More Resources

Pattern Recognition as a Quality Superpower

Pattern Recognition as a Quality Superpower

There are always new ways and reasons to apply pattern recognition to quality improvement. Better ensuring patient outcomes in health care facilities and improving accuracy for medical diagnoses are two such frontiers.
Record Control for a Regulated World

Record Control for a Regulated World

In a regulated industry, the prevailing posture of regulatory representatives, in my experience, has been “Show me proof.” In fact, the philosophy I’ve heard repeated by regulators is “If it wasn’t documented, it didn’t happen.”
EU MDR SSCP’s: The Importance of Readability

EU MDR SSCP’s: The Importance of Readability

Among many of the new requirements that EU MDR has introduced, the Summary of Safety and Clinical Performance (SSCP) is certainly one of the more confusing ones for many firms. SSCP’s are required for implantable and Class III devices under EU MDR and is intended to be a public document summarizing important safety and clinical performance information about the device.

Ready to learn more about working with us?

Pin It on Pinterest

Share This